We are constantly improving our website and we kindly ask for your feedback.
The following survey is anonymous and will take you less than 4 minutes to fill out.
Roche is deeply committed to supporting the global response to put an end to the COVID-19 pandemic. Around the world, we are working with urgency, passion and purpose each and every day to deliver high quality tests that are essential for healthcare systems and patients alike.
Timely availability and fast access to reliable, high quality tests are essential for healthcare systems.
Chief Executive Officer of Roche Diagnostics
Real-time RT-PCR test
The cobas® SARS-CoV-2 Test is a real-time RT-PCR test intended for the qualitative detection of SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples from patients.
This test can run on Roche’s fully automated cobas® 6800 and cobas® 8800 Systems under Emergency Use Authorization. The test is also available for countries accepting the CE-mark.
The Elecsys® Anti-SARS-CoV-2 is an immunoassay for the in vitro qualitative detection of antibodies (including IgG) to SARS-CoV-2 in human serum and plasma. The test is intended as an aid in the determination of the immune reaction to SARS-CoV-2.
The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers.
Reliable diagnostic tests targeting patients that are currently infected by the virus, as well as those that have an immune response against the virus, are valuable. However, it is important to understancd which tests are most suitable to use depending on their intended purpose.
*Whether immunity is gained by individuals who have been infected with SARS-CoV-2 is yet to be confirmed due to the novelty of the virus. Data presented here are based on current scientific understanding of the disease (April 2020)
Watch this video which explains the different diagnostic tests available for SARS-CoV-2 and when they are most effectively used.
COVID-19: coronavirus disease 2019
RT-PCR: reverse transcription polymerase chain reaction